Review of recent months, page-52

"Those are centres that have paid for Cardiocel, they are not numbers based on any sort of trial basis"

or close to those words:
Tom Riester, General Manager, Americas. 06:30

http://www.finnewsnetwork.com.au/Presentations/ASX_Spotlight_Series_2015/March15/Admedus.html

I don't know why this issue of free patches keeps surfacing. The reported sales are just that, sales. It is not going to include "trial/introductory/freebie/whatever" patches and never has. So the margins are on actual sales too.

It's centres using that are the primary no. investors need to concentrate on and Haplo's doing a great job there.

Everyone knows that the surgeons will effectively be selling the product for us, once critical momentum has been reached, and imo that has either happened or we are close, closer every day in fact.

I am waiting for accruals but the 4C commentary will be interesting guidance. It'll be an interesting Thursday.